Oncology Drug Reference Sheet: Mirvetuximab Soravtansine-Gynx
Kimberly Rivera, DNP, RN-BC, OCN®, NPD-BC
Voice
Description
After a single-arm clinical trial demonstrated an overall response rate of 31.7% in 106 patients with folate receptor (FR) alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, the U.S. Food and Drug Administration granted mirvetuximab soravtansine-gynx (Elahere™) accelerated approval on November 14, 2022.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education